Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607774 | 0.92 | F10 (0.43) | F10ITGB3ITGA2BPRSS1PRSS2 | |
| SCHEMBL6635493 | 0.92 | F10 (0.43) | F10ITGB3ITGA2BPRSS1PRSS2 | |
| SCHEMBL6638749 | 0.88 | F10 (0.42) | F10 | |
| SCHEMBL6607865 | 0.88 | MAOA (0.44) | F10ITGB3ITGA2BPRSS1PRSS2 | |
| SCHEMBL6608545 | 0.86 | F10 (0.44) | F10 | |
| SCHEMBL6638409 | 0.86 | F10 (0.47) | F10 | |
| SCHEMBL6607184 | 0.85 | F10 (0.43) | F10 | |
| SCHEMBL6608501 | 0.85 | MAOA (0.52) | F10ABCB11 | |
| SCHEMBL6678975 | 0.84 | F10 (0.47) | F10ITGB3ITGA2BPRSS1PRSS2 | |
| SCHEMBL6678382 | 0.83 | F10 (0.42) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686363-B2 | EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-02-03 | — | — | US | claimed |
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | claimed |
| US-6686363-B2 | EFFECTIVE AGAINST MULTI-RESISTANT BACTERIA | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225107-A1 | CYCLOPROPYL CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | ALAD, OXA1L, ECI1 | F10 3591/4885ITGB3 2390/4885ITGA2B 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.